Alpha 2.0
Login Register
» Authors » Alessandro Broccoli

Alessandro Broccoli

Explore the profile of Alessandro Broccoli including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 127
Citations 1111
Followers 0
Related Specialties
Oncology
Hematology
Pathology
Top 10 Co-Authors
Pier Luigi Zinzani
Lisa Argnani
Vittorio Stefoni
Cinzia Pellegrini
Beatrice Casadei
Letizia Gandolfi
Enrico Derenzini
Alice Morigi
Laura Nanni
Michele Cavo
Published In
Hematol Oncol
Clin Lymphoma Myeloma Leuk
Leuk Lymphoma
Ann Hematol
Oncologist
Affiliations
Soon will be listed here.
Recent Articles
1.
Broccoli A, Zinzani P
Recenti Prog Med . 2025 Mar; 116(3):e37-e39. PMID: 40084457
No abstract available.
2.
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice
Pellegrini C, Casadei B, Broccoli A, Cantelli M, Gugliotta G, Gentilini M, et al.
Ann Hematol . 2025 Mar; PMID: 40025210
Immune checkpoint inhibitors (CPIs) emerged as an effective and safe therapeutic option for patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). However, many patients lose their response to CPIs. To...
3.
Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study
Casadei B, Argnani L, Broccoli A, Cantelli M, Gugliotta G, Gentilini M, et al.
Blood Adv . 2025 Feb; PMID: 39993241
No abstract available.
4.
Broccoli A, Zinzani P
Recenti Prog Med . 2025 Feb; 116(2):e21-e23. PMID: 39931888
No abstract available.
5.
Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib
Broccoli A, Del Re M, Danesi R, Zinzani P
J Cell Mol Med . 2025 Jan; 29(3):e70170. PMID: 39887627
Bruton tyrosine kinase (BTK), the primary target of BTK inhibitors, is a key enzyme in the proliferation and survival pathway of neoplastic B-cells. BTK inhibitors are approved in many hematologic...
6.
Broccoli A, Zinzani P
Recenti Prog Med . 2025 Jan; 116(1):1e-3e. PMID: 39840878
No abstract available.
7.
Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma
Di Staso R, Casadei B, Locke F, Jain M, Voorhees T, Kittai A, et al.
Blood Cancer J . 2024 Nov; 14(1):197. PMID: 39511146
No abstract available.
8.
Efficacy and Safety of Frontline Single-Agent Rituximab in Extranodal Marginal Zone Lymphoma
Mazzoni C, Argnani L, Casadei B, Broccoli A, Gabrielli G, Fabbri N, et al.
Eur J Haematol . 2024 Sep; 114(1):70-78. PMID: 39295142
First-line therapy for patients with extranodal marginal zone lymphoma (EMZL) is not well established, except for eradication therapy for Helicobacter pylori in early gastric MZL. Various regimens, for example, locoregional...
9.
Routine follow-up practices in patients with lymphoma: a nationwide survey by the Italian lymphoma foundation
Broccoli A, Margiotta-Casaluci G, Pagani C, Steffanoni S, Viviani S, Zinzani P, et al.
Leuk Lymphoma . 2024 Sep; 65(14):2207-2210. PMID: 39225366
No abstract available.
10.
Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors-The MicroLinf Study
Casadei B, Conti G, Barone M, Turroni S, Guadagnuolo S, Broccoli A, et al.
Hematol Oncol . 2024 Aug; 42(5):e3301. PMID: 39104142
Biomarkers for immune checkpoint inhibitors (ICIs) response and resistance include PD-L1 expression and other environmental factors, among which the gut microbiome (GM) is gaining increasing interest especially in lymphomas. To...